Linzagolix for endometriosis-associated pain: key secondary efficacy endpoints from edelweiss 3, A phase 3, randomized, double-bind, placebo-controlled trial

Key Points

• Significant improvements in pain outcomes were observed with linzagolix treatment, supporting its efficacy in managing endometriosis-associated pain.
• The trial demonstrated that linzagolix produced noticeable changes in primary and secondary efficacy endpoints within 12 weeks of treatment.
• Conducted as a phase 3, randomized controlled trial, the study compared linzagolix against a placebo to assess its impact on pain relief.
• These findings suggest linzagolix may be a valuable option for treating endometriosis-related pain, urging further exploration in clinical settings.

Abstract